Literature DB >> 22272940

Visfatin serum levels are increased in women with preeclampsia: a case-control study.

E Zorba1, D Vavilis, C A Venetis, V Zournatzi, D Kellartzis, B C Tarlatzis.   

Abstract

OBJECTIVE: Visfatin has been implicated in the pathogenesis of preeclampsia with limited and contradictory, however, results. The aim of this study was to investigate the potential association between visfatin serum concentration and preeclampsia.
METHODS: Visfatin was determined in the serum of 38 women with preeclampsia and 38 women with uncomplicated pregnancies, matched for age and gestational age.
RESULTS: Similar baseline characteristics were present between the two groups in terms of age, body mass index, parity and gravidity. Serum visfatin was significantly increased in the preeclamptic women (median=10.3 ng/mL; interquartile range [IQR] =20) as opposed to their matched controls (median=2.6 ng/mL; IQR=1.4) (p<0.001). Univariate analysis revealed a strong linear correlation of visfatin levels with systolic (r=0.505, p<0.001), diastolic (r=0.467, p<0.001) and mean arterial blood pressure (r=0.497, p<0.001), as well as with uric acid concentrations in the serum (r=0.463, p<0.001). A receiver operating characteristics curve analysis illustrated that serum visfatin concentration is helpful in discriminating between preeclamptic or nonpreeclamptic women with an area under the curve of 0.887 (95% confidence interval [CI]: 0.794-0.948; p<0.001).
CONCLUSION: Visfatin serum concentration seems to be increased in preeclampsia as compared with uncomplicated pregnancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22272940     DOI: 10.3109/14767058.2012.657275

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  4 in total

1.  Adipokine profiles in preeclampsia.

Authors:  Suchitra Chandrasekaran; Hayley Hunt; Susan Melhorn; Hilary S Gammill; Ellen A Schur
Journal:  J Matern Fetal Neonatal Med       Date:  2019-01-09

2.  Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.

Authors:  M R Luizon; A C T Palei; V A Belo; L M Amaral; R Lacchini; G Duarte; R C Cavalli; V C Sandrim; J E Tanus-Santos
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

3.  Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy.

Authors:  Marcelo R Luizon; Vanessa A Belo; Ana Ct Palei; Lorena M Amaral; Riccardo Lacchini; Valeria C Sandrim; Geraldo Duarte; Ricardo C Cavalli; Jose E Tanus-Santos
Journal:  Hypertens Res       Date:  2015-02-26       Impact factor: 3.872

Review 4.  The Role of the Adipokines in the Most Common Gestational Complications.

Authors:  Paweł Gutaj; Rafał Sibiak; Maurycy Jankowski; Karina Awdi; Rut Bryl; Paul Mozdziak; Bartosz Kempisty; Ewa Wender-Ozegowska
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.